Emtricitabine/Tenofovir disoproxil Krka d.d. is an HIV medicine that is used in combination with at least one other HIV medicine to treat adults infected with human immunodeficiency virus type 1 (HIV 1), a virus that causes acquired immune deficiency syndrome (AIDS). In addition, it may be used in adolescents who are resistant to first-line treatments or who cannot take them because of side effects. Emtricitabine/Tenofovir disoproxil Krka d.d contains two active substances, emtricitabine and tenofovir disoproxil. It is a ‘generic medicine’. This means that it contains the same active substances and works in the same way as a ‘reference medicine’ already authorised in the EU called Truvada.
Therapeutic Indication
### Therapeutic indication Emtricitabine/Tenofovir disoproxil Krka d.d. is indicated in antiretroviral combination therapy for the treatment of HIV-1 infected adults. Emtricitabine/Tenofovir disoproxil Krka d.d. is also indicated for the treatment of HIV-1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.
Therapeutic Area (MeSH)
ATC Code
J05AR03
ATC Item
tenofovir disoproxil and emtricitabine
Pharmacotherapeutic Group
Antivirals for systemic use
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| emtricitabine | N/A | 恩曲他滨 |
| tenofovir disoproxil succinate | N/A | Tenofovir disoproxil succinate |
EMA Name
Emtricitabine/Tenofovir disoproxil Krka d.d.
Medicine Name
Emtricitabine/Tenofovir disoproxil Krka d.d.
Aliases
N/ANo risk management plan link.
